Novo Nordisk starts recruitment for combination trial of semaglutide and Astrazeneca tablet

The new phase I study aims to determine whether diabetes treatments semaglutide and dapagliflozin can be combined in one pill.

Photo: Novo Nordisk / PR

Is it possible to create a diabetes tablet which improves treatment by combining several existing products in one pill?

This is what Novo Nordisk is investigating in a new phase I study of an experimental diabetes tablet which combines its own GLP-1 analog, semaglutide, with Astrazeneca’s SGLT2 inhibitor dapaglifozin, which is used in products including Forxiga.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs